Jonathan Allen Webster, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Johns Hopkins University School Of Medicine - Baltimore MD
Rank: Instructor
Years: 2017-2018

Johns Hopkins University School Of Medicine - Baltimore MD
Rank: Assistant Professor
Years: 2018-Present

None Reported

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Leukemia Research
Date: 10 2017

Acute myeloid leukemia in the elderly: therapeutic options and choice.
Leukemia and Lymphoma
Volume: 59
Date: 02 2018

The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Clinical Therapeutics
Volume: 41
Date: 01 2019

Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia.
American Journal of Hematology
Volume: 95
Date: 05 2020

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Blood Advances
Volume: 20
Date: 10 2020

A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syn
Leukemia and Lymphoma
Volume: 62
Date: 12 2021

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
Leukemia Research
Volume: 111
Date: 12 2021

Treatment of AML Relapse After Allo-HCT.
Frontiers in Oncology
Volume: 11
Date: 12 2021